MaravirocのPK/PDモデル

• Maria C. Rosario, et al. (2008) BJCP, "Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients"
  • USD29.95
• Maria C. Rosario, et al. (2005) CPT, "A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc"
  • USD32
• Maria C. Rosario, et al. (2006) J Acquir Immune Defic Syndr, "A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc"

---

• Philippe Jacqmin, Lynn McFadyen & Janet R. Wade (2008) BJCP, "A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc"
  • こちらは未読。